Recursion Pharmaceuticals, Inc. (RXRX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $3.94 (-6.96%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Sep 4, 2024 | Gil Blum | Needham | $11.00 | +178.8% |
| Sep 3, 2024 | Scott Schoenhaus | KeyBanc | $12.00 | +204.2% |
| Sep 3, 2024 | Dennis Ding | Jefferies | $6.00 | +52.1% |
| Jun 26, 2024 | Scott Schoenhaus | KeyBanc | $16.00 | +305.6% |
Top Analysts Covering RXRX
RXRX vs Sector & Market
| Metric | RXRX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.25 | 2.41 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | +49.6% | +153002.0% | +21.5% |
| P/E Ratio | -2.79 | 3.47 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $13M | $27M | $40M | 2 |
| 2027-03-31 | $11M | $24M | $35M | 2 |
| 2027-06-30 | $11M | $23M | $33M | 2 |
| 2027-09-30 | $11M | $24M | $35M | 2 |
| 2027-12-31 | $24M | $52M | $75M | 2 |
| 2028-12-31 | $441M | $441M | $441M | 2 |
| 2029-12-31 | $158M | $248M | $462M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.37 | $-0.24 | $-0.07 | 2 |
| 2027-03-31 | $-0.39 | $-0.24 | $-0.08 | 2 |
| 2027-06-30 | $-0.37 | $-0.23 | $-0.07 | 1 |
| 2027-09-30 | $-0.36 | $-0.23 | $-0.07 | 1 |
| 2027-12-31 | $-0.32 | $-0.20 | $-0.06 | 2 |
| 2028-12-31 | $-0.95 | $-0.45 | $-0.24 | 3 |
| 2029-12-31 | $-2.00 | $-0.94 | $-0.50 | 4 |
Frequently Asked Questions
What is the analyst consensus for RXRX?
The consensus among 3 analysts covering Recursion Pharmaceuticals, Inc. (RXRX) is Buy with an average price target of $5.30.
What is the highest price target for RXRX?
The highest price target for RXRX is $16.00, set by Scott Schoenhaus at KeyBanc on 2024-06-26.
What is the lowest price target for RXRX?
The lowest price target for RXRX is $6.00, set by Dennis Ding at Jefferies on 2024-09-03.
How many analysts cover RXRX?
3 analysts have issued ratings for Recursion Pharmaceuticals, Inc. in the past 12 months.
Is RXRX a buy or sell right now?
Based on 3 analyst ratings, RXRX has a consensus rating of Buy (2.33/5) with a +49.6% upside to the consensus target of $5.30.
What are the earnings estimates for RXRX?
Analysts estimate RXRX will report EPS of $-0.24 for the period ending 2026-12-31, with revenue estimated at $27M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.